PTC/SB/08x (08-03)
Approved for use through 07/31/2006. ONB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006 (DMB 051-4 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMME! Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it confiars a valid OMB control run

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		
	Filing Date		2006-07-12
	First Named Inventor Dierk		k Schoen
(Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	WEBE-0020-US

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	er Kind Code ¹ Issue Date Name of Patentee or Ap				Releva		Lines where ges or Relev		
	1	4966969		1990-1	0-30	Sato et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publ		p				d buttor			
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	74
	1	1067053	EP		A1	2001-01-10	Leuze Electronic G & Co.	SmgH			
	2	50000283	DE		U1	2002-08-22	Jenoptik Jena Gm	ьн			
	3	10058480	DE		A1	2002-06-06	Wenglor Sensoric				

Application Number Filing Date 2006 07-12 Fil

Siemens AG

C2 1981-09-10

DE

	5	4328366	DE	СЗ	1995-03-02	IFM Electronic GmgH			
	6	19521361	DE	A1	1996-12-19	Siemens AG			
	7	10116019	DE	A1	2002-10-10	Basch GmbH Robert			
	8	19504608	DE	A1	1996-08-14	Balluff Gebhard Feinmech			
	9	4442478	DE	A1	1995-06-14	Mitsubishi Electric Corp.			
	10	20106871	DE	U1	2001-08-02	Siemens AG			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add		
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.								Тs	
	_							_	

If you wish to add additional non-patent literature document citation information please click the Add button Add

4 3008309

	Application Number			
INFORMATION DIGGS COURT	Filing Date		2006-07-12	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dien		Schoen	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number		WEBE-0020-US	

	Auditiey Docket Nulliber	WEDE-0020-00				
EXAMINER SIGNATURE						
Examiner Signature		Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Ninc Cotes of USPTO Patent Documents at invent USPTO_GOV/ or MPEP 90104. 2 Enter office that issued the document, by the two-letter OW/IPPO Standard ST3.) 3 "For Jupanese patent document, the architecture of the patent office patent office patent document. A for office counter of the patent office paten

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Diagra can	37	CER 1	97	and	1 98 to	make the	annronniato	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ionii oi tile signatare.	office alguatore.									
Signature	/John A. Merecki/	Date (YYYY-MM-DD)	2006-07-12							
Name/Print	John A. Merecki	Registration Number	35812							

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.